Comparing human epidermal growth factor receptor 2 amplification and expression using immunohistochemistry and silver in situ hybridisation in gastric carcinoma and lymph node metastasis

Gülten,Gülsün; Yilmaz,Bayram; Demi̇rka,Neşe   Çalli

doi:10.3892/ol.2020.11731

Comparing human epidermal growth factor receptor 2 amplification and expression using immunohistochemistry and silver in situ hybridisation in gastric carcinoma and lymph node metastasis

Authors:
- Gülsün Gülten
- Bayram Yilmaz
- Neşe Çalli Demi̇rka
View Affiliations

Affiliations: Department of Pathology, Şanlıurfa Training and Research Hospital, 63250 Şanlıurfa, Turkey, Department of Pathology, Hitit University Erol Olçok Training and Research Hospital, 19040 Çorum, Turkey, Department of Pathology, Faculty of Medicine, Pamukkale University, 20160 Denizli, Turkey
Published online on: June 11, 2020 https://doi.org/10.3892/ol.2020.11731
Pages: 1897-1905
Copyright: © Gülten et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Detecting the amplification and expression of human epidermal growth factor receptor (HER2) is important for planning trastuzumab treatment for patients with gastric carcinoma. The present study aimed to analyse HER2 amplification and expression in primary gastric adenocarcinoma tumours and metastatic lymph nodes using microarray methods, and to assess the potential contribution of these methods to treatment planning. In total, 60 patients with lymph node metastasis were included in the present study. Microarray blocks were obtained from the tissue blocks of primary tumours and metastatic lymph nodes. HER2 expression and amplification were investigated using immunohistochemical and silver in situ hybridisation (SISH) methods, respectively. Following immunohistochemical evaluation of HER2 in primary tumours, the sensitivity and specificity of the microarray method relative to the single block method were 69 and 100%, respectively. For HER2 detection in microarray block sections from primary tumours, the sensitivity and specificity of the SISH method relative to immunohistochemistry were 56 and 100%, respectively. When using SISH in microarray blocked sections, there was a high degree of concordance (98% concordance rate) between HER2 amplification in the primary tumour and the metastatic lymph node. Furthermore, the sensitivity and specificity of metastatic lymph node results relative to those of the primary tumour were 100 and 98%, respectively. Overall, the single block method was more reliable compared with the microarray method for planning treatment. When microarray blocking was used, a large number of samples must be tested to ensure reliable results. The immunohistochemical method is recommended as the first step as SISH alone increases the risk of false‑negative results. Assessing HER2 amplification for treatment planning would be beneficial for primary tumours, as well as metastatic lymph nodes.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clın. 68:394–424. 2018. View Article : Google Scholar
2	Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, et al: Amplification of HER-2 in gastric carcinoma: Association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 16:273–278. 2005. View Article : Google Scholar : PubMed/NCBI
3	Jørgensen JT and Hersom M: HER2 as a prognostic marker in gastric cancer-a systematic analysis of data from the literature. J Cancer. 3:137–144. 2012. View Article : Google Scholar : PubMed/NCBI
4	Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, et al: HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 51:1371–1379. 2006. View Article : Google Scholar : PubMed/NCBI
5	Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omura Y, Satoh T, et al: ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
6	Cortés-Funes H, Rivera F, Alés I, Márquez A, Velasco A, Colomer R, García-Carbonero R, Sastre J, Guerra J and Grávalos C: Phase II of trastuzumab and cisplatin in patients with advanced gastric cancer with HER2/neu overexpression/amplification. J Clin Oncol. 25 (Suppl 18):46132007. View Article : Google Scholar
7	Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Brümmendorf TH, Bokemeyer C, et al: HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 40:769–777. 2009. View Article : Google Scholar : PubMed/NCBI
8	Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y, Fujino MA and Ooi A: Status of c-erbB-2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer. 98:833–837. 2002. View Article : Google Scholar : PubMed/NCBI
9	Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J and Henkel T: Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology. 52:797–805. 2008. View Article : Google Scholar : PubMed/NCBI
10	Kim MA, Lee HJ, Yang HK, Bang YJ and Kim WH: Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology. 59:822–831. 2011. View Article : Google Scholar : PubMed/NCBI
11	Francis GD, Jones MA, Beadle GF and Stein SR: Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: Correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagn Mol Pathol. 18:88–95. 2009. View Article : Google Scholar : PubMed/NCBI
12	Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM and Hortobagyi GN: The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 14:320–368. 2009. View Article : Google Scholar : PubMed/NCBI
13	Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M and Ochiai A: Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 15:65–71. 2006.PubMed/NCBI
14	Grabsch H, Sivakumar S, Gray S, Gabbert HE and Müller W: HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value- conclusions from 924 cases of two independent series. Cell Oncol. 32:57–65. 2010.PubMed/NCBI
15	Drev P, Grazio SF and Bracko M: Tissue microarrays for routine diagnostic assessment of HER2 status in breast carcinoma. Appl Immunohistochem Mol Morphol. 16:179–184. 2008. View Article : Google Scholar : PubMed/NCBI
16	Simon R, Nocito A, Hübscher T, Bucher C, Torhorst J, Schraml P, Bubendorf L, Mihatsch MM, Moch H, Wilber K, et al: Patterns of Her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst. 93:1141–1146. 2001. View Article : Google Scholar : PubMed/NCBI
17	Bozzetti C, Negri FV, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, Gardini G, Nizzoli R, Leonardi F, Gasparro D, et al: Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer. 104:1372–1376. 2011. View Article : Google Scholar : PubMed/NCBI
18	Kochi M, Fujii M, Masuda S, Kanamori N, Mihara Y, Funada T, Tamegai H, Watanabe M, Suda H and Takayama T: Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes. Diagn Pathol. 8:1912013. View Article : Google Scholar : PubMed/NCBI
19	Ieni A, Barresi V, Caltabiano R, Caleo A, Bonetti LR, Lanzafame S, Zeppa P, Caruso RA and Tuccari G: Discordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: A multicenter retrospective analysis. Int J Mol Sci. 15:22331–22341. 2014. View Article : Google Scholar : PubMed/NCBI
20	Pagni F, Zannella S, Ronchi S, Garanzini C and Leone BE: HER2 status of gastric carcinoma and corresponding lymph node metastasis. Pathol Oncol Res. 19:103–109. 2013. View Article : Google Scholar : PubMed/NCBI
21	Bosman FT, Carneiro F, Hruban RH and Theise ND: World Health Organisation classification of tumors of the digestive system. IARC; Lyon: 2010
22	Simon R, Mirlacher M and Sauter G: Tissue microarrays. Methods Mol Med. 114:257–268. 2005.PubMed/NCBI
23	David L, Seruca R, Nesland JM, Soares P, Sansonetty F, Holm R, Børresen AL and Sobrinho-Simões M: C-erbB-2 expression in primary gastric carcinomas and their metastases. Mod Pathol. 5:384–390. 1992.PubMed/NCBI
24	Asioli S, Maletta F, Verdun di Cantogno L, Satolli MA, Schena M, Pecchioni C, Botta C, Chiusa L, Molinaro L, Conti L, et al: Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer. Hum Pathol. 43:2070–2079. 2012. View Article : Google Scholar : PubMed/NCBI
25	Ge X, Wang H, Zeng H, Jin X, Sujie A, Xu C, Liu Y, Huang J, Ji Y, Tan Y, et al: Clinical significance of assessing Her2/neu expression in gastric cancer with dual tumor tissue paraffin blocks. Hum Pathol. 46:850–857. 2015. View Article : Google Scholar : PubMed/NCBI
26	National Comprehensive Cancer Network clinical practice guidelines in oncology (version 2.2015), . Gastric cancer.
27	Tominaga N, Gotoda T, Hara M, Hale MD, Tsuchiya T, Matsubayashi J, Kono S, Kusano C, Itoi T, Fujimoto K, et al: Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer. Gastric Cancer. 19:553–560. 2016. View Article : Google Scholar : PubMed/NCBI
28	Warneke VS, Behrens HM, Böger C, Becker T, Lordick F, Ebert MPA and Röcken C: Her2/neu testing in gastric cancer: Evaluating the risk of sampling errors. Ann Oncol. 24:725–733. 2013. View Article : Google Scholar : PubMed/NCBI
29	Stahl P, Seeschaaf C, Lebok P, Kutup A, Bockhorn M, Izbicki JR, Bokemeyer C, Simon R, Sauter G and Marx AH: Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol. 15:72015. View Article : Google Scholar : PubMed/NCBI
30	Werner D, Battmann A, Steinmetz K, Jones T, Lamb T, Martinez M, Altmannsberger HM and Al-Batran SE: The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testting. J Transl Med. 12:1602014. View Article : Google Scholar : PubMed/NCBI
31	Kim MA, Jung JE, Lee HE, Yang HK and Kim WH: In situ analysis of HER2 mRNA in gastric carcinoma: Comparison with fluorescence in situ hybridization, dual-color silver in situ hybridization, and immunohistochemistry. Hum Pathol. 44:487–494. 2013. View Article : Google Scholar : PubMed/NCBI
32	Fusco N, Rocco EG, Del Conte C, Pellegrini C, Bulfamante G, Nuovo FD, Romagnoli S and Bosari S: HER2 in gastric cancer: A digital image analysis in pre-neoplastic, primary and metastatic lesions. Mod Pathol. 26:816–824. 2013. View Article : Google Scholar : PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI